Loading...

EVOK EVOKE PHARMA INC Management Changes 8-K Filing

VK P

VK

EVOKE PHARMA INC

(EVOK)

2025 8-K

Financial Results

Merger Agreement Signed

Financial Results Announcement

New Product Launches

Patent Allowance

Financial Statements

Financial Results

Director Appointment

Q3 Financial Results

Study Presentation

Director Appointment

Lease Amendment

Warrant Amendments

Nasdaq Compliance

Q2 Financial Results

Reverse Stock Split

Warrant Amendment

Compliance with Nasdaq List...

Appointment of CFO, Salary ...

Financial Results Announcement

Financial Restatement

Warrant Amendment

Appointment of CEO

Nasdaq Listing Rule Compliance

Financial Results Announcement

Equity Offering

Entry into a Material Defin...

Financial Results Announcement

Real-world data on cost-sav...

Lease Amendment

Earnings Report

Non-Compliance Warning

Financial Results Announcement

Approval of Amendment and R...

Presentation Announcement

Patent Issuance

Patent Approval

Data on positive impact of ...

Financial Results Announcement

Abstract Selection

Appointment of Certain Offi...

Dismissal of Patent Infring...

External Links:

On February 20, 2025, Evoke Pharma appointed Greg Pyszcymuka as a Class I director, effective immediately, with options to purchase 5,833 shares of common stock as part of his compensation.

AI Assistant

EVOKE PHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.